Inflamed synovial phagocytic cells (ISPCs)

Inflamed synovial phagocytic cells, primarily consisting of activated synovial macrophages (Type A synoviocytes), are a key cellular component in the pathogenesis of inflammatory arthritides such as rheumatoid arthritis. These cells accumulate in the synovial lining and sublining, where they contribute to joint destruction by secreting pro-inflammatory cytokines (e.g., TNF-alpha, IL-6), chemokines, and matrix metalloproteinases. In the context of drug development, they are often viewed as a cellular target rather than a single molecular target. Therapeutic strategies frequently exploit the overexpression of specific markers on these cells, such as Folate Receptor Beta (FR-beta), to achieve selective delivery of anti-inflammatory drugs or imaging agents. While they are central to the disease process, the term refers to a heterogeneous cell population rather than a specific protein or receptor, making it a cellular target for localized or ligand-mediated therapy.

Other names

Activated synovial macrophagesSynovial lining macrophagesType A synoviocytesInflammatory synovial macrophages

Drugs typically target these cells by binding to overexpressed surface receptors (such as Folate Receptor Beta) to deliver cytotoxic payloads or imaging contrast agents, or by inhibiting the pro-inflammatory cytokines (TNF-alpha, IL-1) they secrete.